Genetic Polymorphisms of Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia

Overview

Journal J Pers Med

Date 2021 Apr 3

PMID 33807811

Citations 9

Authors

Diana Z Paderina

Anastasiia S Boiko

Ivan V Pozhidaev

Anna V Bocharova

Irina A Mednova

Olga Yu Fedorenko

Elena G Kornetova

Anton J M Loonen

Arkadiy V Semke

Nikolay a Bokhan

Svetlana A Ivanova

Affiliations

Soon will be listed here.

Abstract

Background: Antipsychotic-induced metabolic syndrome (MetS) is a multifactorial disease with a genetic predisposition. Serotonin and its receptors are involved in antipsychotic-drug-induced metabolic disorders. The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor () genes , , , and and the gene encoding for the serotonin transporter with MetS in patients with schizophrenia.

Methods: A set of nine single-nucleotide polymorphisms of genes of the serotonergic system was investigated in a population of 475 patients from several Siberian regions (Russia) with a clinical diagnosis of schizophrenia. Genotyping was performed and the results were analyzed using chi-square tests.

Results: Polymorphic variant rs521018 () was associated with higher body mass index in patients receiving long-term antipsychotic therapy, but not with drug-induced metabolic syndrome. Rs1150226 () was also associated but did not meet Hardy-Weinberg equilibrium.

Conclusions: Our results indicate that allelic variants of genes may have consequences on metabolic parameters. MetS may have too complex a mechanistic background to be studied without dissecting the syndrome into its individual (causal) components.

Citing Articles

Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia.

Mednova I, Pozhidaev I, Tiguntsev V, Bocharova A, Paderina D, Boiko A Biomedicines. 2024; 12(3).

PMID: 38540239 PMC: 10968077. DOI: 10.3390/biomedicines12030627.

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Deng S, Xu Q, Jiang W, Hong B, Li B, Sun D BMC Psychiatry. 2023; 23(1):740.

PMID: 37821875 PMC: 10568781. DOI: 10.1186/s12888-023-05240-7.

Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.

Bo Q, Wang X, Liu X, Sang H, Xun Z, Zhang R BMC Psychiatry. 2023; 23(1):115.

PMID: 36810039 PMC: 9945355. DOI: 10.1186/s12888-023-04598-y.

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome.

Boiko A, Mednova I, Kornetova E, Goncharova A, Semke A, Bokhan N J Pers Med. 2022; 12(10).

PMID: 36294794 PMC: 9604670. DOI: 10.3390/jpm12101655.

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance.

Wu H, Wang X, Liu X, Sang H, Bo Q, Yang X Front Psychiatry. 2022; 13:935769.

PMID: 36061293 PMC: 9435526. DOI: 10.3389/fpsyt.2022.935769.

References

Reynolds G, Zhang Z, Zhang X . Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002; 359(9323):2086-7. DOI: 10.1016/S0140-6736(02)08913-4. View

Opgen-Rhein C, Brandl E, Muller D, Neuhaus A, Tiwari A, Sander T . Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics. 2010; 11(6):773-80. DOI: 10.2217/pgs.10.50. View

Reynolds G . Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol. 2004; 18(3):340-5. DOI: 10.1177/026988110401800303. View

Higgins G, Fletcher P, Shanahan W . Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol Ther. 2019; 205:107417. DOI: 10.1016/j.pharmthera.2019.107417. View

Loonen A, Ivanova S . Evolution of circuits regulating pleasure and happiness with the habenula in control. CNS Spectr. 2017; 24(2):233-238. DOI: 10.1017/S1092852917000748. View

Andreasen N, Pressler M, Nopoulos P, Miller D, Ho B . Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2009; 67(3):255-62. PMC: 3677042. DOI: 10.1016/j.biopsych.2009.08.040. View

Papanastasiou E . The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol. 2013; 3(1):33-51. PMC: 3736963. DOI: 10.1177/2045125312464385. View

Pozhidaev I, Paderina D, Fedorenko O, Kornetova E, Semke A, Loonen A . 5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. Front Mol Neurosci. 2020; 13:63. PMC: 7193905. DOI: 10.3389/fnmol.2020.00063. View

Karunakaran S, Clee S . Genetics of metabolic syndrome: potential clues from wild-derived inbred mouse strains. Physiol Genomics. 2017; 50(1):35-51. DOI: 10.1152/physiolgenomics.00059.2017. View

10.

Voigt J, Fink H . Serotonin controlling feeding and satiety. Behav Brain Res. 2014; 277:14-31. DOI: 10.1016/j.bbr.2014.08.065. View

11.

Reynolds G, Zhang Z, Zhang X . Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry. 2003; 160(4):677-9. DOI: 10.1176/appi.ajp.160.4.677. View

12.

Stancakova A, Laakso M . Genetics of metabolic syndrome. Rev Endocr Metab Disord. 2014; 15(4):243-52. DOI: 10.1007/s11154-014-9293-9. View

13.

Penninx B, Lange S . Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018; 20(1):63-73. PMC: 6016046. View

14.

Matsumoto-Miyai K, Yoshizumi M, Kawatani M . Regulatory Effects of 5-Hydroxytryptamine Receptors on Voiding Function. Adv Ther. 2015; 32 Suppl 1:3-15. DOI: 10.1007/s12325-015-0240-2. View

15.

De Hert M, Detraux J, van Winkel R, Yu W, Correll C . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2):114-26. DOI: 10.1038/nrendo.2011.156. View

16.

Freyberg Z, Aslanoglou D, Shah R, Ballon J . Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Front Neurosci. 2017; 11:432. PMC: 5532378. DOI: 10.3389/fnins.2017.00432. View

17.

Malhotra N, Grover S, Chakrabarti S, Kulhara P . Metabolic syndrome in schizophrenia. Indian J Psychol Med. 2013; 35(3):227-40. PMC: 3821198. DOI: 10.4103/0253-7176.119471. View

18.

Wyler S, Lord C, Lee S, Elmquist J, Liu C . Serotonergic Control of Metabolic Homeostasis. Front Cell Neurosci. 2017; 11:277. PMC: 5611374. DOI: 10.3389/fncel.2017.00277. View

19.

Li P, Tiwari H, Lin W, Allison D, Chung W, Leibel R . Genetic association analysis of 30 genes related to obesity in a European American population. Int J Obes (Lond). 2013; 38(5):724-9. PMC: 3909018. DOI: 10.1038/ijo.2013.140. View

20.

Souza R, De Luca V, Meltzer H, Lieberman J, Kennedy J . Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics. 2010; 20(4):274-6. DOI: 10.1097/FPC.0b013e328337ce3e. View